Intellia Therapeutics (NTLA) 10-K2019 FY Annual report
Filed: 27 Feb 20, 4:34pm
- NTLA Dashboard
- Financials
- Data
- Institutional
- Insider
- News
- Filings
- Transcripts
- ESG
- Shorts
- Patents
-
10-K Filing
Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing files
SEC
- 10-K Annual report
- 4.4 Instruments defining the rights of security holders, including indentures
- 10.21 Material contracts
- 21.1 Subsidiaries of the registrant
- 23.1 Consent of experts and counsel
- 31.1 Management certification of annual or quarterly disclosure
- 31.2 Management certification of annual or quarterly disclosure
- 32.1 Management certification of annual or quarterly disclosure
- Download Excel data file
- View Excel data file
Associated NTLA transcripts
Related press release
Filing tables
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
abdominal, affinity, airway, al, angioedema, Article, Asia, assumption, Banerji, BfArM, Bipartisan, blend, borrow, borrowing, bradykinin, breathing, Brexit, Bristol, buildup, burden, CCPA, cloud, CMMI, CMO, Codification, codified, collateralized, consecutive, curve, cybersecurity, debilitating, dehydrogenase, depiction, District, dividend, Eastern, EC, electorate, enzymatic, EPO, esterase, Euro, Expert, expiry, explanatory, germline, GMP, HAE, Helsinki, herewith, hybrid, hydroxyacid, ICTRP, imaging, impasse, implicit, Importantly, indefinitely, inline, inseverable, instability, instructed, intestinal, intrinsic, Judge, judgement, justify, kallikrein, lactate, land, Latin, Laura, Ldha, leaseback, Leasehold, leaving, left, lengthier, LSC, main, manipulation, mathematical, MatterThe, meaningfully, MHRA, Milan, mispairing, month, monthly, nausea, NEJM, noncurrent, Northern, nurse, opt, opted, oxidase, pain, painful, Parliament, PCT, perpetual, pharmacovigilance, PIP, plain, pre, prekallikrein, proactively, project, proportionate, propriety, quantify, qui, reactivity, reconsider, redeclared, referendum, regenerate, regime, registry, regular, rejected, remanded, reward, RMP, Roche, safer, server, somatic, Squibb, sublease, supplementary, swelling, tam, terrorist, tract, transgene, trauma, twelve, undergone, uninsured, unregulated, vanilla, Verve, vomiting
Removed:
amyloidotic, augmentation, belong, Casebia, central, CLL, combine, commencing, contemplated, contested, COPD, counter, credited, culminate, developmental, discontinued, discontinuing, elastase, electrical, escalation, exercisable, FAC, familial, FAP, gained, graft, inclusive, infancy, infection, inflammation, informing, inherited, Juno, leasing, lessee, lung, metabolic, metabolism, MML, muscle, neutrophil, obstructive, patentably, pattern, permanently, procedure, protease, pulmonary, quantity, recording, redeemable, redemption, relocate, relocation, remeasured, scarring, secrete, secreted, split, systematically, technique, transplantation, unit, unprotected
NTLA similar filings
Filing view
Table of contents
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-227814 and 333-233448 on Form S-3 and Registration Statement Nos. 333-211200, 333-218511 and 333-229900 on Form S-8 of our reports dated February 27, 2020, relating to the financial statements of Intellia Therapeutics, Inc., and the effectiveness of Intellia Therapeutics, Inc.’s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP |
|
Boston, Massachusetts |
|
February 27, 2020 |
|